Biopharmaceuticals

The Supreme Court Kept the Door Open to Genus ClaimsThe Seventh Circuit Asks, “What’s Wrong With Having Lots of Patents?”BridgeBio Transaction Reflects Healthy Market for FDA Priority Review Vouchers

Biosimilars

The Supreme Court Kept the Door Open to Genus ClaimsThe Seventh Circuit Asks, “What’s Wrong With Having Lots of Patents?”BridgeBio Transaction Reflects Healthy Market for FDA Priority Review Vouchers

Biotechnology

The Supreme Court Kept the Door Open to Genus ClaimsUpdate on Artificial Intelligence: USPTO Urges Federal Circuit to Affirm Decision That AI Cannot Qualify as an “Inventor”Preparing for Europe’s Unified Patent Court

Commercial Litigation

Is an Appeal Time Well-Spent? For Patents, That Depends . . .When Nondisclosure Agreements and Pharmaceutical Trade Secrets IntersectArbitration Clause Not Binding on the United States Patent Office

Diagnostics

In the Orphan Drug Approval Race, Winner Takes All? Ramifications of Catalyst Pharms. v. BecerraSynthetic Data Gets Real

Generics

“Negative” Patent Claim Limitations—May They be Adequately Described by Omission?Preparing for Europe’s Unified Patent CourtSkinny Labels May Not Be Dead: Delaware District Court Distinguishes GSK, Dismisses Induced Infringement Claim

IPR

When Is Less Really More for a Patent Licensee?I’ve Been Sued for Patent Infringement… Is an IPR Worthwhile?

Medical Devices

U.S. Medical Device Manufacturers Should Take Note of New European Medical Device RegulationsPrior Art Showing An Invention To Be “At Least Possible” Found Sufficient To Invalidate Surgical Device PatentFederal Circuit Invalidates Device Patent As Directed to an Abstract Idea

Patents

The Supreme Court Kept the Door Open to Genus ClaimsIs an Appeal Time Well-Spent? For Patents, That Depends . . .The Seventh Circuit Asks, “What’s Wrong With Having Lots of Patents?”

Privacy & Cybersecurity

U.S. Medical Device Manufacturers Should Take Note of New European Medical Device RegulationsSynthetic Data Gets Real

PTAB

Is an Appeal Time Well-Spent? For Patents, That Depends . . .When (Patent) Success Isn’t ObviousArbitration Clause Not Binding on the United States Patent Office

Therapeutics

BridgeBio Transaction Reflects Healthy Market for FDA Priority Review VouchersUpdate on Artificial Intelligence: USPTO Urges Federal Circuit to Affirm Decision That AI Cannot Qualify as an “Inventor”Preparing for Europe’s Unified Patent Court